Time to Become Negative of Three Rapid Diagnostic Tests for Malaria

Malaria, Falciparum Clinical Trial

Official title:

Time to Become Negative of Three Rapid Diagnostic Tests for Malaria in Children Under 5 Years of Age. Evaluation in Two Different Malaria Epidemiological Settings in Greater Mbarara District, South Western Uganda

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01325974
• Other study ID #: Epicentre/Mba/2011/TTBN-RDTmal
• Status: Completed
• Phase: N/A
• First received: March 29, 2011
• Last updated: November 26, 2015
• Start date: September 2011
• Est. completion date: May 2013

Study information

• Verified date: November 2015
• Source: Epicentre
• Contact: n/a
• Is FDA regulated: No
• Health authority: Uganda: Research Ethics Committee
• Study type: Observational

Clinical Trial Summary

Background: Antigen-detecting rapid diagnostic tests (RDTs) for malaria provide the possibility of a parasite-based diagnosis in areas where good quality microscopy can not be achieved.

P. falciparum tests targeting the histidine-rich protein (HRP2) antigen are generally more sensitive than tests targeting the Plasmodium lactate dehydrogenase (pLDH) antigen. However, as the HRP2 antigen is eliminated from the bloodstream more slowly than the pLDH antigen, HRP2-based tests can give a positive result two weeks or more after the patient has taken an effective treatment, while pLDH tests generally turn negative a few days after. The use of an RDT positive result in a routine patient care is therefore challenged by the interpretation of whether the result is due to a lasting effect of the already treated infection or to a new infection. The interpretation might also be affected by the level of malaria transmission in the area.

Objective: The objective of this study is to estimate the proportion of positive tests in patients successfully treated for malaria (smear negative) at different time points in time after treatment, for three rapid diagnostic tests: SD Bioline Malaria Antigen P.f. (catalogue number: 05FK50-02-4), CareStart Malaria HRP2 (Pf) (catalogue number: G0141) and CareStart Malaria pLDH (PAN) (catalogue number: G0111). The study will be carried out in two settings with known low and high malaria transmission levels in order to provide guidance of interpretation of a RDT positive result depending on the intensity of malaria transmission.

Secondary objectives will be to measure the sensitivity and specificity of the malaria rapid tests compared to smear microscopy, to estimate the median time to become negative for each of the tests and to estimate the proportion of positive tests and the median time to become negative according to the initial parasitaemia and the presence of gametocytes.

Description:

The study population will be patients under 5 years of age who attend the consultation service of one health centre of Mbarara municipality (low transmission setting) and one health centre in Kazo sub-county (high transmission setting) and for whom the clinical diagnosis of malaria is confirmed by smear microscopy and with at least one positive RDT. Patients with general signs of danger of severe malaria or who took a full course of antimalarial treatment in the previous 2 weeks will be excluded. Written consent will be sought from all participants.

A total of 212 patients will be included in each setting. The sample size was based of a minimum accuracy of 8% around a proportion of 50% positive RDTs to which a 15% was added for patients who will not be positive for all RDTs or will be secondarily excluded from the analysis.

A three-day artemether-lumefantrine will be given to enrolled cases and treatment intake will be supervised. RDTs and a blood smear microscopy will be repeated at day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after inclusion until all RDTs become negative. Follow-up will not last longer than 42 days.

The proportion and 95% confidence intervals of positive tests among patients with a negative thick smear will be calculated for each day of follow-up. Moreover the investigators will identify for each test a regression model to estimate the number of days required to obtain a 50, 25, 10 and 5% probability of having a false positive RDT result.

Sensitivity, specificity, positive and negative predictive values will be estimated for each RDT independently using the result of microscopy as a reference. The analysis will be performed using the day 0 results for all patients enrolled in the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 424
• Est. completion date: May 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 5 Years

Eligibility

Inclusion Criteria (sensitivity/specificity analysis):

• Age under 5 years

• Clinical malaria defined as fever (axillary temperature = 37.5°C) or history of fever in the previous 48 hours

• Weight = 5 kg

• Informed consent given by the parent or a tutor

Additional inclusion criteria (time to become negative analysis):

• Positive blood smear with a Plasmodium falciparum monoinfection at the day of inclusion

• At least one RDT positive at the day of inclusion

• High probability of coming to all follow-up visits

Exclusion Criteria (time to become negative analysis):

• General signs of danger or of severe malaria according to the WHO criteria

• Treatment course of antimalarials in the previous 2 weeks

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Malaria
• Malaria, Falciparum

Locations

Country	Name	City	State
Uganda	Kazo level 4 health centre	Kazo	Greater Mbarara District
Uganda	Mbarara Municipality level 2 health centre	Mbarara	Greater Mbarara district

Sponsors (2)

Lead Sponsor	Collaborator
Epicentre	Medecins Sans Frontieres

Country where clinical trial is conducted

Uganda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To estimate the proportion of positive tests in patients successfully treated for malaria (smear negative) at different time points after treatment, for three rapid diagnostic tests: two HRP2 test and one pLDH test.		day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after the start of antimalarial treatment intake	No
Secondary	To measure the sensitivity and specificity of the malaria rapid tests compared to smear microscopy.		The day of patient's enrollment only (day 0)	No
Secondary	To estimate the median time to become negative for each of the rapid diagnostic test.		day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after the start of antimalarial treatment intake	No
Secondary	To estimate the proportion of positive tests among smear negative results and the median time to become negative according to the initial parasitaemia and the presence of gametocytes.		day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after the start of antimalarial treatment intake	No